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(GSFQ) is a speciﬁc Quality of Life (QoL) instrument which
measures the impact of GERD symptoms on QoL. This study
aims to adapt the GSFQ into Spanish (for Spain) culture and
check the questionnaire psychometric properties. METHODS:
An expert panel composed by a gastroenterologist, two method-
ologists, one expert in clinical research and one pharmacoecono-
mist supervised the adaptation process. The original instrument
was translated and back-translated by two independent transla-
tors. For psychometric measures, a small sample was used to
check the initial comprehension and factibility. A national rep-
resentative sample was selected, stratiﬁed by gender, age (<45,
45 years) and GERD severity (0-I, II, Savary-Miller score).
Content validity was ensured by the original instrument. Cron-
bach’s Alfa was used to assess reliability, and exploratory factor
analysis to assess dimensionality. The EuroQol questionnaire and
corresponding Visual analogue scales (VAS) were used for con-
current validity. RESULTS: A total of 3997 patients with pyrosis
symptoms were recruited by 490 clinicians. Mean age was 49.35
(14.35) years and 48.4% were women. No ceiling or ﬂoor effects
were detected in item responses. The reliability was good (0.864)
and only 1 dimension exhibited an eigenvalue (3.45) above 1,
explaining 58% of available variability. All items loaded on
this dimension. Correlation were moderate but signiﬁcant
(p < 0.001) with EuroQol (0.499) and VAS (-0.481). The
average score was 34.17 (19.685), in the 0–100 scale. Mean
scores were signiﬁcantly different between GERD diagnosed
severity levels (F4,33035 = 84.9, p < 0.005), but no differences were
found between Savary-Miller level IV and levels II-III. CON-
CLUSION: The Spanish version of the GSFQ has good psycho-
metric properties, behaves as a unidimensional scale, and is
capable to discriminate between patients with varying degrees of
GERD severity.
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OBJECTIVES: According to recently published guidelines,
treatments effects on patient’s health status should be measured
by validated disease-speciﬁc Patient Reported Outcomes con-
cepts. The aim of this study is to develop and validate a PRO
questionnaire based on a conceptual framework for Crohn’s
disease. METHODS: An item pool of 77 items was generated
through in focus groups and validated in a German sample
(n = 104). Other data included the SF-36 and IBDQ. RESULTS:
A principal component analysis revealed 7 independent factors:
impact, intimacy, abdominal pain, bowel movements, nausea,
extraintestinal problems and night sweat. The impact factor
was shown to comprise further three interpretable domains:
emotional, social, and physical. CONCLUSION: Symptoms
and consequences of Crohn’s disease need to be measured sepa-
rately, since their constituent items do not load on the same
factors. Further investigation could reduce the amount of items
of one concept or ﬁnd further items for relevant aspects such as
problems with intimacy.
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OBJECTIVES: To quantify the effects of chronic constipation on
health-related quality of life, work productivity, and activity
impairment. METHODS: Data are taken from the 2005 U.S.
National Health and Wellness Survey, an annual cross-sectional
study of the health care attitudes and behaviors of adults (age
18+). Chronic constipation sufferers are deﬁned as experiencing
chronic constipation in the past twelve months, and non-sufferers
have not experienced chronic constipation. Respondents who
experience inﬂammatory bowel disease or irritable bowel syn-
drome are excluded from the analysis. Quality of life is deﬁned
using the SF-8. The Work Productivity and Activity Impairment
(WPAI) scale is used to quantify productivity loss. Linear regres-
sion models are used to control for potential confounders includ-
ing demographics, number of physical comorbid conditions, and
experiencing psychiatric comorbid conditions. RESULTS: The
sample includes 1,288 (3%) chronic constipation sufferers and
35,676 (97%) non-sufferers. Chronic constipation sufferers
have signiﬁcantly worse mean physical (40.08 versus 48.79,
p < 0.001) and mental (42.13 versus 49.75, p < 0.001) quality of
life than non-sufferers. Controlling for potential confounders,
constipation sufferers have SF-8 physical summary scores that
are 3.550 (p < 0.001) points lower and SF-8 mental summary
scores that are 2.891 (p < 0.001) points lower than non-sufferers.
Among respondents employed full-time, chronic constipation
sufferers have signiﬁcantly greater productivity loss due to absen-
teeism (8.35 versus 3.10, p < 0.001), presenteeism (29.36 versus
13.36, p < 0.001), and overall (25.54 versus 12.18, p < 0.001).
Controlling for potential confounders, constipation sufferers
have greater absenteeism scores (3.102 points higher, p < 0.001),
presenteeism scores (7.782 points higher, p < 0.001), and overall
work productivity loss (6.017 points higher, p < 0.001) than
non-sufferers. Chronic constipation sufferers also experience
greater activity impairment (48.71 versus 21.75, p < 0.001) than
non-sufferers, and have activity impairment scores 11.708 higher
(p < 0.001) after controlling for potential confounders. CON-
CLUSION: Chronic constipation has signiﬁcant negative effects
on physical and mental quality of life, work productivity, and
activity impairment.
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OBJECTIVES: To obtain the multi-attribute utility function
(MAUF) for the Spanish version of the Short Form 6-D (SF-6D)
and to compare utilities values with those determined by the
British MAUF. To determine the weights of SF-36v1 items con-
forming the SF-6D instrument. METHODS: A whole-nation rep-
resentative sample of 2,549 subjects [48.9% men, 48.5 (14.01)
years] with mild to severe degree of Gastroesophageal Reﬂux
Disease was recruited by 500 clinicians selected at random and
used for this analysis. The Spanish versions of SF-6D and EQ-5D
questionnaires plus the corresponding visual analogue scale were
self-completed. Attribute weights were estimated using a cat-
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egorical regression model. First the estimation procedure was
validated through estimation of the MAUF for the EQ-5D
attributes based on the exiting Spanish tariff scores for the instru-
ment. Secondly the MAUF for the SF-6D attributes was esti-
mated regressed on the EQ-5D tariff scores. Weights were
rescaled to yield scores ranging from worse possible state (0) to
full health (1). RESULTS: All estimated attribute weights were
signiﬁcant and goodness of ﬁt was reasonable (R2 = 0.799).
Spanish utility values for the same health states are signiﬁcantly
different from those used in the UK; 0.7458 (0.208) vs. 0.7090
(0.143), p < 0.001. The shape of utility scores obtained with the
Spanish MAUF exhibits a cubic pattern as compared to the
British. Utilities obtained by the Spanish MAUF are higher for
benign health states while severe states attain lower utilities.
CONCLUSION: The proposed method allows for a valid and
reliable estimation of a MAUF based on kwon utilities of a
concurrent instrument, avoiding the need of incomplete designs
to collect preferences. Evident differences between culture
speciﬁc scoring systems encourage adapting instruments to the
target culture in order to obtain valid measures. Spanish weights
for SF-6D are now available to be used with existing or new
SF-36v1 databases.
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OBJECTIVES: The efﬁcacy and safety of certolizumab pegol
(CZP), a PEGylated anti-TNF, in patients with active Crohn’s
disease (CD) have been demonstrated in two 26-week induction
and maintenance trials, PRECiSE 1 (Sandborn et al., 2005) and
PRECiSE 2 (Schreiber et al., 2005). This analysis evaluated the
effect of CZP versus placebo on quality-adjusted life-years
(QALYs) for each subject in these trials. METHODS: In
PRECiSE 1, patients with active CD received double-blind CZP
400 mg (n = 331) or placebo (n = 328) every 4 weeks after induc-
tion. PRECiSE 2 began with an open-label induction period
(CZP 400 mg at Weeks 0, 2 and 4). Patients who demonstrated
a clinical response at Week 6 were randomised to receive CZP
400 mg (n = 215) or placebo (n = 210) every 4 weeks from
Weeks 8 to 24. The EQ-5D was administered at each visit and
converted into utility scores using an established algorithm
(Dolan et al., 1995). An estimate of QALYs was made for each
patient from the area under the utility curve during the randomi-
sation period of each trial. Mean QALYs and standard deviation
(SD) were calculated by treatment group and compared using a
Wilcoxon rank sum test. RESULTS: Over the 26-week PRECiSE
1 trial, the mean (SD) QALYs were 0.5456 (0.2993) for CZP and
0.4797 (0.3121) for placebo. Similarly, between Weeks 6 and 26
of PRECiSE 2, the mean (SD) QALYs were 0.4976 (0.2047) in
the CZP group versus 0.4286 (0.2171) in the three injection
followed by placebo group. A statistically signiﬁcant gain in
QALYs with CZP was observed in both trials: PRECiSE 1 0.0659
(p = 0.001); PRECiSE 2 0.0690 (p = 0.015). CONCLUSION:
CZP improved both quality and quantity of remission and
response period, as measured by QALYs, signiﬁcantly more than
placebo among patients with CD in two 26-week maintenance
trials.
PGI29
UPPER GI SYMPTOMS IN GREEK PATIENTS RECEIVING
ASPIRIN/NSAIDS
Papatheodoridis G1,Vaskantiras V2, Daskos G2,
Christodoulopoulou A2
1Ippokration General Hospital, Athens, Greece, 2AstraZeneca SA,
Athens, Greece
OBJECTIVES: Non-steroidal anti-inﬂammatory drugs (NSAIDs)
and Aspirin are among the most widely used drugs, particularly
for long-term treatment of arthritic disorders in primary care.
Aspirin/NSAIDs cause upper-gastrointestinal symptoms. This
study aimed to assess the nature and frequency of Upper-GI
symptoms (GERD and/or Dyspepsia) experienced by patients
receiving Aspirin and/or NSAIDs and to depict the current clini-
cal practice in the ﬁeld of gastroprotection of patients receiving
these drugs. METHODS: A total of 1604 individuals (M/F:
743/861, age 58.3713.1 years, BMI 27.5  3.7 Kg/m2) visiting
189 Primary Care Practitioners between June-July 2006 were
included. A structured questionnaire was used to record
demographic/medical history data including Aspirin/NSAIDs
use, the antisecretory treatment received together with Aspirin/
NSAIDs and the presence of GERD (heartburn, regurgitation)
and Dyspepsia (epigastric pain, early satiety, postprandial full-
ness) symptoms, which were based on widely accepted epidemio-
logical criteria. RESULTS: The main indications for patients
receiving Aspirin/NSAIDs were backache (16.7%), osteoarthritis
(14.5%), coronary artery disease (8.9%) and rheumatoid arthri-
tis (5.6%). Upper-GI symptoms (GERD and/or Dyspepsia) for
2 days/week were reported by 71.7% of participants. GERD
was reported by 57.3% and Dyspepsia by 54.8% of participants,
while 40.3% of them experienced symptoms of both diseases.
Antisecretory treatment was used by 78.8% of participants (PPIs
75.8%, H2-antagonists 20.2%, Antacids 8.2%). Upper-GI
symptoms of 2 day’s per/week were reported by 70.5% of
patients who received antisecretory treatment compared to
76.8% of those who did not (P < 0.025). Patients receiving
PPI experienced upper-GI symptoms by 66.2%, signiﬁcantly
less compared to 83.9% of H2-antagonists/Antacids users
(P < 0.001). CONCLUSION: Upper-GI symptoms are present in
approximately 3/4 of Aspirin/NSAIDs users. Antisecretory treat-
ment reduces Upper-GI symptoms, with PPIs being signiﬁcantly
superior than H2–antagonists/Antacids. However, in primary
care, a substantial proportion of Aspirin/NSAIDs users remain
symptomatic despite the use of antisecratory agents and therefore
other parameters such as adherence to antisecratory treatment
should be further investigated.
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OBJECTIVES: To estimate demand and supply of blood prod-
ucts in Bavaria, as due to intransparency on prices and trade
volumes reliable data are missing and to support optimal plan-
ning of blood supply and usage in Bavaria within the next two
decades. METHODS: Data were collected through desk-top
researches on demographics (e.g. Federal Statistical Ofﬁce
Germany, Bavarian State Ofﬁce for Statistics and Data Process-
ing), blood usage and donation behaviour in Germany (Robert
Koch Institute, Paul-Ehrlich-Institute, Bavarian Red Cross) and
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